What does DR. NICK DE RYCK ALGEMENE GENEESKUNDE do?

DR. NICK DE RYCK ALGEMENE GENEESKUNDE is a general practice in Dilbeek. Private Limited, started on 15 October 2021, 1 establishment.

What is the address of DR. NICK DE RYCK ALGEMENE GENEESKUNDE?

The registered office of DR. NICK DE RYCK ALGEMENE GENEESKUNDE is located at Schorenbosstraat 8 A, 1703 Dilbeek.

Is DR. NICK DE RYCK ALGEMENE GENEESKUNDE still active?

Yes. According to the CBE (29 September 2026) DR. NICK DE RYCK ALGEMENE GENEESKUNDE is active, legal situation “Normale toestand”, started on 15 October 2021.

Is DR. NICK DE RYCK ALGEMENE GENEESKUNDE registered on Peppol?

Yes, DR. NICK DE RYCK ALGEMENE GENEESKUNDE is registered on the Peppol network with ID 0208:0775787291.

What is the enterprise number of DR. NICK DE RYCK ALGEMENE GENEESKUNDE?

The enterprise number of DR. NICK DE RYCK ALGEMENE GENEESKUNDE is BE0775787291.

When was DR. NICK DE RYCK ALGEMENE GENEESKUNDE founded?

DR. NICK DE RYCK ALGEMENE GENEESKUNDE was founded on 15 October 2021.

Who are the directors of DR. NICK DE RYCK ALGEMENE GENEESKUNDE?

According to the 2025 annual accounts, the directors of DR. NICK DE RYCK ALGEMENE GENEESKUNDE are: Nick De Ryck.

Is DR. NICK DE RYCK ALGEMENE GENEESKUNDE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 October 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. NICK DE RYCK ALGEMENE GENEESKUNDE make in 2025?

DR. NICK DE RYCK ALGEMENE GENEESKUNDE posted a profit after taxes of € 78,533 in financial year 2025.

What is the revenue of DR. NICK DE RYCK ALGEMENE GENEESKUNDE?

As a small company, DR. NICK DE RYCK ALGEMENE GENEESKUNDE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 137,483.

DR. NICK DE RYCK ALGEMENE GENEESKUNDE (Private Limited)

Dossier DR. NICK DE RYCK ALGEMENE GENEESKUNDE, printed on 29 September 2026 from databakkes.be/en/0775787291/dr-nick-de-ryck-algemene-geneeskunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. NICK DE RYCK ALGEMENE GENEESKUNDE from Dilbeek, company number BE0775787291, closed financial year 2025 with a result of € 78,533 after tax. For that financial year DR. NICK DE RYCK ALGEMENE GENEESKUNDE recorded a gross margin of € 137,483 and equity of € 125,775. Compared with financial year 2024, the result moved from € 63,995 to € 78,533. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Healthy

€ 125,775

▼ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 78,533

▲ 23% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 183,868

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 141,500 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost

€ 32,265

▲ 12% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 915

▼ 43% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2,093

▲ 21% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 121,944 Gross margin 2022: € 121,944 First fiscal year in the series	€ 114,356 Gross margin 2023: € 114,356 ▼ 6% vs 2022 (€ 121,944) Unfavourable step	€ 118,826 Gross margin 2024: € 118,826 ▲ 4% vs 2023 (€ 114,356) Favourable step	€ 137,483 Gross margin 2025: € 137,483 ▲ 16% vs 2024 (€ 118,826) Favourable step	▲ 16%
Profit after taxes	€ 61,810 Profit after taxes 2022: € 61,810 First fiscal year in the series	€ 60,370 Profit after taxes 2023: € 60,370 ▼ 2% vs 2022 (€ 61,810) Unfavourable step	€ 63,995 Profit after taxes 2024: € 63,995 ▲ 6% vs 2023 (€ 60,370) Favourable step	€ 78,533 Profit after taxes 2025: € 78,533 ▲ 23% vs 2024 (€ 63,995) Favourable step	▲ 23%
Equity	€ 66,010 Equity 2022: € 66,010 First fiscal year in the series	€ 125,580 Equity 2023: € 125,580 ▲ 90% vs 2022 (€ 66,010) Favourable step	€ 188,742 Equity 2024: € 188,742 ▲ 50% vs 2023 (€ 125,580) Favourable step	€ 125,775 Equity 2025: € 125,775 ▼ 33% vs 2024 (€ 188,742) Unfavourable step	▼ 33%
Total debts	€ 26,570 Total debts 2022: € 26,570 First fiscal year in the series	€ 60,634 Total debts 2023: € 60,634 ▲ 128% vs 2022 (€ 26,570) Unfavourable step	€ 44,314 Total debts 2024: € 44,314 ▼ 27% vs 2023 (€ 60,634) Favourable step	€ 159,188 Total debts 2025: € 159,188 ▲ 259% vs 2024 (€ 44,314) Unfavourable step	▲ 259%
Cash	€ 73,920 Cash 2022: € 73,920 First fiscal year in the series	€ 168,387 Cash 2023: € 168,387 ▲ 128% vs 2022 (€ 73,920) Favourable step	€ 183,660 Cash 2024: € 183,660 ▲ 9% vs 2023 (€ 168,387) Favourable step	€ 183,868 Cash 2025: € 183,868 Unchanged (€ 183,660) Favourable step
Retained profit	€ 61,010 Retained profit 2022: € 61,010 First fiscal year in the series	€ 120,580 Retained profit 2023: € 120,580 ▲ 98% vs 2022 (€ 61,010) Favourable step	€ 183,742 Retained profit 2024: € 183,742 ▲ 52% vs 2023 (€ 120,580) Favourable step	€ 120,775 Retained profit 2025: € 120,775 ▼ 34% vs 2024 (€ 183,742) Unfavourable step	▼ 34%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 800) Unchanged	€ 833 Dividend 2024: € 833 ▲ 4% vs 2023 (€ 800) Unchanged	€ 141,500 Dividend 2025: € 141,500 ▲ € 140,667 vs 2024 (€ 833) Unchanged	▲ € 140,667
Balance sheet total	€ 92,579 Balance sheet total 2022: € 92,579 First fiscal year in the series	€ 186,214 Balance sheet total 2023: € 186,214 ▲ 101% vs 2022 (€ 92,579) Unchanged	€ 233,056 Balance sheet total 2024: € 233,056 ▲ 25% vs 2023 (€ 186,214) Unchanged	€ 284,963 Balance sheet total 2025: € 284,963 ▲ 22% vs 2024 (€ 233,056) Unchanged	▲ 22%

Key figures of DR. NICK DE RYCK ALGEMENE GENEESKUNDE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. NICK DE RYCK ALGEMENE GENEESKUNDE?

What happened at DR. NICK DE RYCK ALGEMENE GENEESKUNDE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 14, 2026 New annual accounts for financial year 2025: profit of € 78,533 (▲ 23% vs 2024). Source: NBB ↗
Oct 15, 2021 New establishment in Dilbeek. KBO
2021 Nick De Ryck became a director. NBB
Oct 15, 2021 Start of the company according to the CBE. KBO

In short

From € 61,810 profit in 2022 to € 78,533 profit in 2025.

Paid € 88,381 in corporate taxes since 2022.

Best year ever: 2025, with € 78,533 profit.

Paid out € 143,933 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. NICK DE RYCK ALGEMENE GENEESKUNDE? We notify you, reason included.

Follow DR. NICK DE RYCK ALGEMENE GENEESKUNDE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Nick De Ryck

DR. NICK DE RYCK ALGEMENE GENEESKUNDE

Schorenbos

Behind DR. NICK DE RYCK ALGEMENE GENEESKUNDE is Nick De Ryck. Nick De Ryck is also behind Schorenbos.

See the full network in the app

Directors

According to the 2025 annual accounts

Nick De Ryck

Director

Also active at: Schorenbos

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Schorenbosstraat 8 A

1703 Dilbeek

2.323.116.940

Schorenbosstraat 8 box A

1703 Dilbeek

Active since 15 October 2021

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0775.787.291
VAT number: BE 0775.787.291
Registered office: Schorenbosstraat 8 A, 1703 Dilbeek
Names & denominations: DR. NICK DE RYCK ALGEMENE GENEESKUNDE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 15 October 2021
Peppol: Active · Active since 13 Mar 2026
Activities · NACE: Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗